XenaTri
Pantethine - is a conjugate of the vitamin Pantethinic acid and the low molecular weight aminothiol cysteamine. Pantethine is quickly converted to Coenzyme A in the body. The following supportive benefits are associated with more than 30 years of global scientific research data where Pantethine supplementation occurred at 600-900 mg/day.
Pantethine Supports:
Increasing Diet Effectiveness – Studies support that hyperlipidemic patients with uncomplicated high lipid profiles, and even for those associated with diabetes have effective responses when not amenable to satisfactory correction of blood lipids by diet alone. Clin Ther 1986. Also patients who eat high cholesterol diets tend to have lower blood cholesterol levels when on Pantethine then those who are not. Atherosclerosis, May 1980.
Hyperlipidemic Diabetic Patients – Pantethine was shown as a very effective hypolipemic agent in diabetic patients on dialysis or without dialysis with a great tolerance. Am J Nephrol, 1991; Clin Ter, March, 1989; Artery, 1987.
Decreasing Platelet and Plasma Cholesterol – Pantethine supports the reduction of phospholipids and cholesterol content in the plasma and platelets of patients with elevated lipid profiles. Angiology, March, 1987; Int J Clin Pharmacol Res, 1985; Atherosclerosis, December, 1984.
Decreasing Platelet and Plasma Cholesterol in Children – Pantethine supports the significant reduction of TC, LDL, Triglycerides, and Apo-B and a significant increase in HDL and Apo A-I in children with excellent tolerability and effectiveness. Int J Clin Pharm Ther Tox, November, 1986.
Decreasing HMG-CoA Reductase Activity – Pantethine supports the inhibition of HMG-CoA Reductase activity as well as a more distal enzyme in the cholesterol synthetic pathway to more than half there usual activity in synthesizing cholesterol in the liver. Med Hypotheses, March, 2001; Biochim Biophy Acta, November, 1988; J Lipid Res, February, 1987; Atherosclerosis, April, 1986.
Decreasing Blood Pressure - Pantethine supports the reduction of vasopressin in the posterior pituitary and hypothalamus suggesting the support of assisting in maintaining a target blood pressure. Life Sci, 1990.
Increases HDL Cholesterol - Studies support that Pantethine results in a significant improvement of HDL-C. Minerva Med, June, 1990; Atherosclerosis, January, 1984.
Lowers LDL Cholesterol - Pantethine supports the significant reduction of LDL cholesterol and its peroxidation for men and women. Minerva Med, June, 1990; Atherosclerosis, January, 1984.
Lowers Triglycerides - Pantethine research data with 600 mg/day support its use as a powerful agent to aid in the lowering of Triglycerides. J Atheroscler Thromb, 2000; Arzneimittelforschung, 1985.
Increases Apo A-I and Apo A-II - HDL-C contains the beneficial subfraction proteins Apo A-I and Apo A-II. In the case of coronary heart disease and elevated TC these subfractions are decreased. Pantethine supports the increase of these HDL-C proteins. Artery. 1985; Atherosclerosis, February, 1982.
Decrease of Aortic and Coronary Atheromatous Lesions - Pantethine supports the improvement of elevated serum lipoproteins and the prevention of the incidence of atheromatous lesions in the aorta and coronary artery. Jpn J Pharmacol, June, 1986.
Antiarrhythmic Activity - Pantethine is known to convert to coenzyme A and has been reported to support antiarrhythmic action on experimental cardiac arrhythmias by prolonging action potential duration and effective refractory period. Jpn Heart J, March, 1985.
